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An Overview of Leber’s Hereditary Optic Neuropathy 
Introduction 
Albrecht von Graefe, a Prussian ophthalmologist, noted in 1858 that an adolescent male 
patient of his developed unusual acute central vision loss in both eyes over the course of several 
months [1]. Nearly fifteen years passed before another ophthalmologist by the name of Theodor 
Leber began to take serious note of this anomaly and characterized the disorder [2]. Leber noted 
that the condition strongly favored males and seemed to be heritable, indicating a genetic basis 
for the disease. Due to the work of Thomas Morgan several years earlier, Leber determined that 
the inheritance patterns of the disease must be due to a sex-linked recessive trait. Unfortunately 
the inheritance patterns were not as clear-cut as the experiments Morgan conducted because 
males peculiarly failed to pass the disease to their offspring. Nearly a hundred years later 
additional researchers realized that the disease followed the inheritance patterns of maternal 
cytosolic inheritance, not of genomic DNA [3]. This evidence strongly suggested that the disease 
takes root in an abnormality in the mitochondrial DNA (mtDNA). The disorder eventually 
became known as Leber’s hereditary optic neuropathy (LHON) and by 1988 the mtDNA-basis 
for the disease was elucidated. Currently there are no established therapies to treat LHON and 
much of the treatment is aimed at prolonging eyesight in those who have the disorder. However, 
there are a number of contemporary therapies that have been shown to improve patient eyesight 
[4]. As a result of its highly structured nature, seemingly insignificant adjustments to the mtDNA 
result in the molecular basis of LHON.   
Molecular Basis of LHON 
There are three primary mutations that result in the development of LHON. Surprisingly, 
each of these defects derives from a single nucleotide point mutation resulting in a dysfunctional 
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protein subunit associated with complex I of the electron transport chain (ETC). The first 
mutation to be identified was found in the gene that codes for NADH dehydrogenase 4 (ND4), 
commonly known as ubiquinone. ND4 is an important and heavily conserved polypeptide 
subunit of NADH dehydrogenase that is responsible for the transfer of electrons between NADH 
to coenzyme Q in the inner membrane of the mitochondria [5]. As indicated previously, proper 
expression of the ND4 gene permits the successful flow of electrons down the ETC, ultimately 
providing the means by which adenosine triphosphate (ATP) synthesis may occur. A mutation in 
this gene will have a deleterious effect, inhibiting the efficiency of ATP formation. One such 
mutation involves a simple nucleotide exchange at position 11778 in the mitochondrial genome. 
For reasons not yet fully understood, a guanine (G) is substituted for an adenine (A), leading to a 
subtle, yet potent change in the primary structure of the protein [6]. The particular mutation in 
ND4 mentioned above is responsible for nearly 70% of the reported cases of LHON [6]. 
Furthermore, the remaining cases largely stem from mutations in related polypeptide subunits of 
ubiquinone—ND1 and ND6, specifically. Like ND4, ND1 and ND6 are also involved in the 
successful transmission of electrons between the NADH and coenzyme Q. Thus, mutations in 
these subunits are also attributed to the LHON condition. As in the case of ND4, the mutation in 
ND1 is caused by a G to A substitution at position 3460 in the mitochondrial genome. A 
mutation in ND6, on the other hand, derives from the substitution of a thymine (T) for a cytosine 
(C) at point 14484 [6]. Together, these three mutations account for approximately 90-95% of all 
LHON cases. The remaining 5-10% are not fully understood, but are expected to also be 
associated with abnormalities in complex I of the ETC [7].  
The ETC is a collection of enzymes responsible for the energy-yielding reactions of the 
cell. These enzymes provide a means by which electron transporters such as NADH and flavin 
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adenine dinucleotide (FADH2) can donate their electrons to release their potential energy in a 
controlled stepwise process, making the harnessing of ATP possible. The association of the ETC 
with the inner mitochondrial membrane is vital for its energy-yielding function. Like 
chloroplasts, mitochondria are double membrane organelles. This provides mitochondria with the 
unique ability to differentially compartmentalize their membranes to allow for selective 
molecular transporting that ultimately produces an electrochemical gradient across the inner 
membrane. This gradient is necessary for the conversion of kinetic energy into potential energy 
in the form of ATP.  
The electron transporters donate electrons to complex I, which passes them to coenzyme 
Q, a hydrophobic electron carrier that resides in the inner membrane space. Coenzyme Q then 
diffuses through the membrane until it reaches complex III. Electrons are transferred to complex 
III, which passes these electrons to cytochrome c, a peripheral protein that resides on the inner 
membrane space side of the membrane. Cytochrome c donates these electrons to complex IV that 
then passes them on to the terminal electron acceptor, oxygen, leading to the formation of 
metabolic water. Throughout this process each complex (with the exception of complex IV) 
effectively pumps hydrogen ions from inside of the mitochondrial matrix to the inner membrane 
space. Via diffusion down the concentration gradient, hydrogen ions pass through the final 
complex and back into the mitochondrial matrix. This complex is known as ATP synthase, 
whose function is often likened to that of a water mill. As hydrogen ions flow down the 
concentration gradient the ATP synthase spins, harnessing the kinetic energy and focusing it on 
the formation of ATP from adenosine diphosphate (ADP) and inorganic phosphate.  
The ETC pathway is conserved and highly regulated in virtually all eukaryotic cells. The 
life of the cell and the organism itself is at risk if one of these enzymes develops a mutation. As 
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mentioned earlier, LHON is caused by a mutation in a single subunit belonging to one of the 
many enzymes described above (viz. complex I). Incredibly, a single nucleotide mismatch in one 
of the enzyme’s many subunits can result in LHON, which speaks to the importance of ensuring 
that this process is accurately regulated.  
A reduction in the cell’s ability to produce ATP ultimately leads to cellular apoptosis. 
However, the question remains: why do these mutations manifest themselves phenotypically as 
an acute onset of blindness? The answer to this question has yet to be fully understood, but 
research suggests that LHON leads to a degeneration of retinal ganglion cells (RGC) and their 
axons due to a deficit in ATP and the formation of a large number of oxygen free radicals. 
Essentially, RGCs are responsible for relaying visual information from photoreceptors in the eye 
and propagating these signals down their axons to the brain [8]. The RGC’s axons compose what 
is collectively known as the optic nerve (Fig. 1).  
 
Fig. 1: Optic Nerve and the Retinal Ganglion Cells. LHON is characterized by a sudden 
decrease in visual activity, which is attributed to the degradation of retinal ganglion cells (RGC) 
and their associated axons. The RGCs reside within the innermost layer of the eye (5) and feed 
their axons to a centralized location at the back of the eye. The axons of all the RGCs compose 
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the optic nerve (6), which relays visual information to the brain. The lobes highlighted above 
constitute the outer most layer of the brain: (1) cross section of the right frontal lobe, (2) parietal 
lobe, (3) occipital lobe, (4) cerebellum (temporal lobe not highlighted). Degradation of the optic 
nerve is responsible for a number of vision-related issues, including LHON. This degradation is 
typically associated with apoptosis of the RGCs, and in the case of LHON it is believed to result 
from a dysfunction of complex I in the ETC leading to an increase in free radicals. 
 
These cells are remarkably active, requiring an incredible amount of ATP to function and survive 
in the extracellular environment [8]. Most cells throughout the body have less stringent ATP 
demands than that of RGCs, which is largely the reason these parts of the body remain 
unaffected by LHON despite having the same genetic makeup. Although research in this area has 
made a considerable number of advancements in recent years, a clear molecular pathway still 
remains to be identified. 
 One of the most interesting characteristics of LHON is its unique pattern of inheritance. 
When a fetus is formed, half of the genetic material is paternal while the other half is maternal, 
creating a diploid organism. Essentially all that is contributed paternally is the genomic 
information in the form of DNA. That said, virtually all of the cellular components of a fertilized 
egg are donated maternally from the mother’s ovum, including the mitochondria and its 
associated mitochondrial genome. Due to the molecular roots of LHON in the mtDNA, the 
disease is not associated with the genomic DNA to which, as stated previously, the male does 
contribute through the nuclear fusion of sperm and ovum. As a result affected males are not able 
to pass the disorder onto their children (Fig. 2).  
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Fig. 2: Inheritance Patterns of LHON and mtDNA-Associated Diseases. LHON pathology 
follows the inheritance pattern of the maternal contribution to a developing fetus. A point 
mutation in one of three genes encoded for by the mtDNA has been shown to be the molecular 
driver of the disorder. As a result, the pathology follows the inheritance of the maternal 
mitochondria. Mating between an affected mother and unaffected father (left) results in 100% of 
affected progeny because the disorder is passed maternally. On the other hand, mating between an 
affected father and unaffected mother (right) would result in 100% unaffected progeny. Due to 
incomplete penetrance, there is no guarantee that symptoms in each of the progeny will occur, if 
ever. Adapted from ghr.nlm.nih.gov, n.p., Retrieved April 18, 2015, from 
http://ghr.nlm.nih.gov/handbook/illustrations.  
 
This mode of inheritance baffled early LHON investigators, including Theodor Leber 
himself. Thomas Morgan unraveled the closest explanation for this pattern of inheritance in the 
early 1900s, shortly before Leber began to make his initial observations. In his lab at Columbia 
University, Morgan identified a pattern of recessive sex-linked inheritance in a number of fruit 
flies (Drosophila melanogaster) with peculiar mutations in eye color. Morgan effectively 
discovered that the chromosomes responsible for male and female differentiation also carry other 
information, particularly for eye color in his model. This inheritance pattern predicted that if an 
affected mother carried the mutated gene on one or both of her X chromosomes, then her male 
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offspring would have an increased risk for the condition over the female siblings. This idea 
fascinated Leber, and managed to explain many of his results. In the end Leber determined that 
this sex-linked inheritance pattern must be the way LHON is passed down from generation to 
generation. Researchers today realize that Leber’s conclusion was premature. His incorrect 
conclusion was largely due to the fact that the field of cellular biology was still in its infancy. 
Although Morgan’s mechanism of inheritance explained why males primarily inherited the 
disease, it failed to explain why these males were incapable of passing the condition to their 
progeny. Nearly 60 years would pass until the discovery of mtDNA. Researchers finally had 
sufficient evidence to theorize that the molecular basis of LHON resides in the mtDNA, not 
genomic DNA. Douglas C. Wallace discovered a point mutation in the ND4 polypeptide in 1988, 
almost 130 years after the first documented case of the disorder [5,6].  
LHON may arise at any age, however the disorder usually affects young males during 
their second or third decade of life [7].1 Interestingly, nearly 50% of males and approximately 
90% of affected females never develop any signs of vision loss, indicating that the disease has a 
level of penetrance associated with the condition [9]. Despite this, affected individuals who are 
asymptomatic may still transmit the disorder to their offspring. Symptoms of LHON are 
characterized by an acute loss of central vision in one eye, followed by the other a few weeks to 
months later [7,9]. Typically, the disorder progresses to the point of severe optic atrophy and 
permanent impairment of visual activity, and in some cases, a total loss of central vision [7]. 
Affected individuals are born with no distinction between their unaffected peers. Once the onset 
of the disorder occurs the only distinguishing feature is their loss of visual activity, although 
                                                 
1 The age of onset is largely a question of penetrance in specific pedigrees. Geographic locations seem to 
also be a contributing factor because some mutations are more prevalent than in other areas of the globe. The 
median age of onset for males worldwide is 22, give or take 2 years depending on the specific mutation [9].  
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some heart-related issues have been reported [7]. Apart from this, individuals remain 
phenotypically indistinguishable from their peers.  
Prevention and Therapies 
Because of the genetic basis of the disease there are no true preventative measures for 
LHON, although avoiding excessive alcohol consumption and smoking may prevent early onset 
of the disease [9]. Many of the therapies currently being developed focus on vision management 
and slowing the progression of the disorder. Several coping methods have been developed for 
those who suffer from LHON, focusing particularly on occupational rehabilitation. Occupational 
rehabilitation for LHON is similar to other forms of visual impairment and is thus made possible 
by the utilization of visual and auditory aids [9]. Technologically enhanced assisted living via 
personal computers and cellphones with text-to-speech capabilities and magnified font sizes is 
common for occupational rehabilitation. Currently, pharmaceutical interventions are being 
developed in which administration of particular drugs could prevent additional vision loss in the 
early stages of LHON [9]. For example, idebenone (previously marketed as Raxone), a synthetic 
analog of coenzyme Q10, has shown some clinical success in treating LHON in its early stages 
[9,10]. Patients have recorded an increase in visual activity shortly after treatment with 
idebenone [10]. Because of this success, authorization for idebenone was submitted to the 
European Medicines Agency (EMA) in January of 2013. Idebenone is believed to function by 
reducing the number of free radicals that form as a byproduct of LHON, thus reducing the 
number of cells that undergo apoptosis. How this works is not entirely understood. As a result of 
this and the fact that idebenone is effective only in those patients who are in the early stages of 
LHON, the EMA rejected this proposal for idebenone authorization [11]. Today researchers are 
working to increase treatment efficacy in the later stages of the disease in the hopes of reapplying 
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for EMA authorization in the future. For individuals who think that they may be at risk for 
LHON, diagnosis of the disorder is primarily concerned with identifying one of three point 
mutations in the mtDNA via qualitative RT-PCR. Additional testing is also not uncommon [12].  
In some studies, phosphorus magnetic resonance spectroscopy was used to distinguish the 
various mutations that result in LHON [9]. Interestingly this technique has also been successful 
in identifying asymptomatic carriers of the disorder. Despite having the same genetic defects, 
these individuals show no signs of the disease. Those who have been diagnosed with LHON may 
want to consider the possibility of speaking with a genetic counselor, particularly in the event of 
family planning. Gene therapy, the selective removal and/or addition of particular genes into 
specific loci, has also been explored as a potential treatment option for LHON. Due to the 
physical nature of the mtDNA, the method of gene therapy is expected to be significantly more 
effective than related methods on genomic DNA [12, 13].2 Implications of this method as a 
treatment option for LHON seem promising, but require further investigations to assess safety 
and efficacy [9]. In asymptomatic carriers, LHON symptoms may be precipitated by nutritional 
deprivation, exposure to toxins, antiretroviral drugs, and even excessive stress. These 
environmental factors have been correlated in individuals who have early onset of the disease, 
however there is no consensus among experts as to the degree of their significance in 
accelerating the disease [9].  
Conclusion 
LHON is a heritable disorder characterized by an acute onset of vision loss that serves as 
a common model for mtDNA-associated disorders. Since its first documented observation in 
                                                 
2 One of the major setbacks for gene therapy in treating genetic disorders is that genomic DNA resides on 
linear chromosomes, preventing the insertion/exertion of specific genes. The circular nature of mtDNA resembles 
yeast and bacterial DNA, which has shown a significant level of success in gene therapy.  
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1858, the molecular basis of LHON has been formulated and remodeled many times over, 
largely due to the gradual scientific revelations over the eras. The exact mutations responsible for 
approximately 90% of all LHON cases have been identified. However, an explanation of how the 
disease manifests itself in the degradation of the optic nerve remains theoretical at best. Despite 
this, researchers are exploring potential therapies for LHON that are proving to be quite 
promising. Contemporary treatments such as gene therapy may prove to be beneficial for 
disorders like LHON. With the combination of occupational rehabilitation therapies as well as 
the potential for pharmaceutical drug intervention, LHON may soon be a manageable disease for 
many of those affected by it. The ultimate goal of treatment is targeted at the reversal of the 
disorder, leading to improved visual activity. Although it may seem like this goal is distant in the 
future, it may actually be closer than it appears.  
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